Group key figures Q4 2021

KDKK 01/10/21 01/10/20 31/12/20 01/01/21 31/12/21 01/01/20 31/12/20
31/12/21
Net sales 874 0 874 0
Operating -4,718 -2,721 -14,509 -5,871
profit
(EBIT)
Result per -0.17 -0.07 -0.52 -0.48
share (DKK)
Equity 0.78 0.89 0.78 -0.89
ratio

Number of shares on the 08/04/20: 175,760
Number of shares on the 26/06/20: 14,060,800
Number of shares on the 02/10/20: 20,730,800
Number of shares on the 30/09/21: 22,433,139
Number of shares on the 31/12/21: 26,551,018

CEO Jeppe Krog Rasmussen, comments:

A remarkably busy and eventful 2021 has come to an end and in the final quarter of 2021, and it feels very satisfying to be able to announce, that we had a turnover for the first time in DanCann Pharma history. Numerous other important milestones have been reached and we are still standing - stronger, firmer and more positive than ever.

Pressing the start button in Biotech Pharm1 and the first harvest, the signing of the exclusive distribution agreement with Canadian Tetra Bio-Pharma, two capital injections, the acquisition of CannGros and the permanent Danish Pilot Programme for production companies combined with a four-year extension of the programme for patients. Important headlines for us.

The acquisition of CannGros and subsequently the sales of products to Danish pharmacies have furthermore resulted in a turnover for the first time in DanCann Pharma history. We are very proud to have reached this milestone.

In Q4 2021 we were busy finalizing the details in our EU-GMP application for Biotech Pharm1, which we have sent to the Danish Medicines Agency in January 2022, with an expected approval from the DMA in the first half of 2022. As a company we are facing another major milestone when we will be ready with our first biomaterial. A biomaterial produced under indoor conditions in closed hermetic chambers under best practice GACP- and EU-GMP conditions. Exiting times ahead.

However, we would not be here without the support and trust from our local community, our employees, and our board of directors. They all believe in DanCann Pharma. Believe that we can make a difference for all of those, who need a company just like us.

Q4 and 2021 have been momentous periods for DanCann Pharma and I am proud of the whole team for the dedication and hard work everyone has shown throughout the year. I am equally excited about what 2022 has in store for us. Finally, I would like to take this opportunity to express my sincere gratitude to all our shareholders. The interest and support we receive from you cannot be overestimated in our quest to provide better treatments to patients.

Highlights during the period

MON, OCT 04, 2021
DanCann Pharma A/S and CannGros ApS entered into an Agreement to which DanCann Pharma will acquire 100% of the shares of CannGros. Through the acquisition, DanCann Pharma obtains all necessary licenses for the import and distribution of medical cannabis, as well as three products (dried flower and granulars) admitted to the list of medical cannabis products under the Danish Pilot Program with medical cannabis. In addition to this, CannGros has a pending application (extracts of cannabis in an oil solution) at the Danish Medicines Agency.

TUE, OCT 05, 2021
The Board of Directors of DanCann Pharma A/S resolved to issue 2,207,399 units, based on the authorization granted by DanCann's extra general meeting on 23 July 2021 and in accordance with the intention to carry out the directed issue of units as communicated by the company on 04 October 2021. The subscription price in the directed issue of units was 3.664 DKK per unit and was determined through a 10-day Volume Weighted Average Price ("VWAP") based on a "accelerated book-building" procedure led by Corpura Fondkommission AB. Through the directed share issue, DanCann received proceeds amounting to approximately 8 MDKK, before deductions for costs related to the directed share issue.

FRI, OCT 08, 2021
DanCann Pharma A/S announced that the Danish Minister of Health, Magnus Heunicke, had submitted a bill to continue the Pilot Programme for medicinal cannabis. In May, the majority of parliamentary parties agreed to extend the Pilot Programme for prescription for Danish patients by four years from 1 January 2022. At the same time, the bill aims to give companies a permanent opportunity to manufacture medicinal cannabis products.

WED, OCT 20, 2021
DanCann Pharma A/S and CannGros ApS has today closed the agreement according to which DanCann Pharma will acquire 100% of the shares of CannGros cf. the press release of 05 October 2021. Through the acquisition, DanCann Pharma obtains all necessary licenses for the import and distribution of medical cannabis, as well as three products (dried flower and granulars) admitted to the list of medical cannabis products under the Danish Pilot Programme with medical cannabis. In addition to this, CannGros has a pending application (extracts of cannabis in an oil solution) at the Danish Medicines Agency.

FRI, OCT 22, 2021
DanCann Pharma A/S announced on behalf of Tetra Bio-Pharma Inc. that Tetra Bio-Pharma - a leader in cannabinoid-derived drug discovery and development - on October 21 informed that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) had issued a positive opinion on the Company's application for Orphan Drug Designation (ODD) for its investigational medicine QIXLEEF™ as a potential treatment for Complex Regional Pain Syndrome (CRPS), a chronic neuropathic pain condition.

TUE, NOV 30, 2021
DanCann Pharma A/S announced on behalf of Tetra Bio-Pharma Inc. that Tetra Bio-Pharma - a leader in cannabinoid-derived drug discovery and development - yesterday announced positive initial clinical data from its ongoing Phase 2 clinical trials (REBORN©1 and PLENITUDE©) of QIXLEEF™ for cancer pain. QIXLEEF™ is a botanical inhaled investigational new drug with a fixed ratio of THC and CBD that meets USA cGMP regulatory requirements.

THU, DEC 02, 2021
DanCann Pharma A/S could proudly announce that that there was broad political support for the proposal to make the current Pilot Programme a permanent scheme. The scheme was adopted exclusively with yes votes (102-0).

FRI, DEC 17, 2021
DanCann Pharma A/S announced that the company CEO, Jeppe Krog Rasmussen (indirectly through his holding company: Xignotus Capital ApS) had chosen to lock his position after talks with the Board of Directors of DanCann Pharma. Jeppe Krog Rasmussen has locked his position in the company for another 36 months with effect from 1 January 2022 up to and including 31 December 2024. Jeppe Krog Rasmussen holds 5,667,023 shares, which constitutes to approx. 21.34% of the total share capital at a fair value as of today (before market open 17 December 2021) of 27,768,412.7 DKK (share price: 4.900).

THU, DEC 30, 2021
DanCann Pharma A/S communicate and comment on the intention from the new government of Germany to legalize controlled sales of cannabis for adults for recreational purposes. The German government estimates that the state can earn 4.7 billion euros (approximately DKK 35 billion) annually on a legalization.

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com